Article
Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease.
Archivos de bronconeumologia - 1 Sept 2023
Carrasco Hernández Laura, Girón Moreno Rosa Mª, Balaguer Cartagena Mari Nieves, Peláez Adrián, Sole Amparo, Álvarez Fernández Antonio, Felipe Montiel Almudena, Olveira Casilda, Olveira Gabriel, Gómez Bonilla Ainhoa, Gómez Crespo Beatriz, García Clemente Marta, Solís García Marta, Quaresma Vázquez Joana, Blitz Castro Enrique, Rodríguez González Jesús, Expósito Marrero Andrea, Diab-Cáceres Laila, Ramos Hernández Cristina, Zamarrón de Lucas Ester, Prados Sanchez Concha, Blanco Aparicio Marina, López Neyra Alejandro, Sanz Santiago Verónica, Luna Paredes Carmen, Delgado Pecellín Isabel, Asensio de la Cruz Óscar, Quintana Gallego Esther
Abstract excerpt
INTRODUCTION: Elexacaftor/tezacaftor/ivacaftor (ETI) was used through the early access programme in Spain from December 2019 in cystic fibrosis (CF) patients with homozygous or heterozygous F508del mutation with advanced lung disease. METHODOLOGY: Multicentre, ambispective, observational, study in which 114 patients in follow-up in 16 national CF units were recruited. Clinical data, functional tests, nutritional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.